Detection of serum SNHG22 and its correlation with prognosis of non-small cell lung cancer.

IF 1.5 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Cardiothoracic Surgery Pub Date : 2024-09-20 DOI:10.1186/s13019-024-03048-4

Quan Cheng, Guoping Chen, Xiaojiao Wu, Hang Fang, Jingjing Shi, Bonian Zhong

{"title":"Detection of serum SNHG22 and its correlation with prognosis of non-small cell lung cancer.","authors":"Quan Cheng, Guoping Chen, Xiaojiao Wu, Hang Fang, Jingjing Shi, Bonian Zhong","doi":"10.1186/s13019-024-03048-4","DOIUrl":null,"url":null,"abstract":"Background: Lung cancer accounts for a significant proportion of cancer-related deaths in China, with the majority of the cases being classified as non-small cell lung cancer (NSCLC). The study aimed to investigate the expression of serum SNHG22 in patients with NSCLC, and its molecular mechanism and prognostic potential in NSCLC.Methods: Admitted 125 NSCLC patients were selected for the study, along with 125 healthy individuals in the same period. The levels of SNHG22 and miR-128-3p were quantified via RT-qPCR. Correlations between the SNHG22 level and the pathological characteristics of the NSCLC patients were investigated through the application of the chi-square test. The targeting relationship between SNHG22 and miR-128-3p was predicted by online database and confirmed by luciferase activity. The prognostic ability of SNHG22 in NSCLC was assessed by Kaplan-Meier curves and multivariate Cox analysis.Results: SNHG22 was upregulated in NSCLC and directly targeted miR-128-3p. The rate of overall survival is lower in patients with high-SNHG22 group compared to those with low-SNHG22 group. Silencing SNHG22 impaired the functionality of cells, which was restored by miR-128-3p inhibitor. SNHG22 stands as an independent predictor of poor prognosis in NSCLC patients.Conclusion: The overexpression of SNHG22 in NSCLC is related to lymph node metastasis, TNM stage and patient survival, which is expected to be a prognostic predictor of NSCLC patients.","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"19 1","pages":"536"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414149/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiothoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13019-024-03048-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lung cancer accounts for a significant proportion of cancer-related deaths in China, with the majority of the cases being classified as non-small cell lung cancer (NSCLC). The study aimed to investigate the expression of serum SNHG22 in patients with NSCLC, and its molecular mechanism and prognostic potential in NSCLC.

Methods: Admitted 125 NSCLC patients were selected for the study, along with 125 healthy individuals in the same period. The levels of SNHG22 and miR-128-3p were quantified via RT-qPCR. Correlations between the SNHG22 level and the pathological characteristics of the NSCLC patients were investigated through the application of the chi-square test. The targeting relationship between SNHG22 and miR-128-3p was predicted by online database and confirmed by luciferase activity. The prognostic ability of SNHG22 in NSCLC was assessed by Kaplan-Meier curves and multivariate Cox analysis.

Results: SNHG22 was upregulated in NSCLC and directly targeted miR-128-3p. The rate of overall survival is lower in patients with high-SNHG22 group compared to those with low-SNHG22 group. Silencing SNHG22 impaired the functionality of cells, which was restored by miR-128-3p inhibitor. SNHG22 stands as an independent predictor of poor prognosis in NSCLC patients.

Conclusion: The overexpression of SNHG22 in NSCLC is related to lymph node metastasis, TNM stage and patient survival, which is expected to be a prognostic predictor of NSCLC patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血清 SNHG22 的检测及其与非小细胞肺癌预后的相关性

背景：在中国，肺癌占癌症相关死亡的很大比例，其中大多数病例被归类为非小细胞肺癌（NSCLC）。本研究旨在探讨血清SNHG22在NSCLC患者中的表达及其在NSCLC中的分子机制和预后潜力：方法：研究选择了125名NSCLC患者和同期的125名健康人。通过 RT-qPCR 对 SNHG22 和 miR-128-3p 的水平进行定量。通过卡方检验研究了 SNHG22 水平与 NSCLC 患者病理特征之间的相关性。通过在线数据库预测了SNHG22与miR-128-3p之间的靶向关系，并通过荧光素酶活性进行了证实。通过Kaplan-Meier曲线和多变量Cox分析评估了SNHG22在NSCLC中的预后能力：结果：SNHG22在NSCLC中上调，并直接靶向miR-128-3p。与低SNHG22组相比，高SNHG22组患者的总生存率较低。沉默SNHG22会损害细胞的功能，而miR-128-3p抑制剂可以恢复细胞的功能。SNHG22是NSCLC患者不良预后的独立预测因子：结论：SNHG22在NSCLC中的过表达与淋巴结转移、TNM分期和患者生存率有关，有望成为NSCLC患者的预后预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cardiothoracic Surgery 医学-心血管系统

CiteScore

2.50

自引率

6.20%

发文量

286

审稿时长

4-8 weeks

期刊介绍： Journal of Cardiothoracic Surgery is an open access journal that encompasses all aspects of research in the field of Cardiology, and Cardiothoracic and Vascular Surgery. The journal publishes original scientific research documenting clinical and experimental advances in cardiac, vascular and thoracic surgery, and related fields. Topics of interest include surgical techniques, survival rates, surgical complications and their outcomes; along with basic sciences, pediatric conditions, transplantations and clinical trials. Journal of Cardiothoracic Surgery is of interest to cardiothoracic and vascular surgeons, cardiothoracic anaesthesiologists, cardiologists, chest physicians, and allied health professionals.